{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:09:49Z","timestamp":1790730589247,"version":"4.1.0"},"reference-count":25,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2022,4,22]]},"DOI":"10.18632\/oncotarget.28226","type":"journal-article","created":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T21:17:20Z","timestamp":1650748640000},"page":"628-640","source":"Crossref","is-referenced-by-count":2,"title":["Bladder cancer survival in patients with <i>NOD2<\/i> or <i>CDKN2A<\/i> variants"],"prefix":"10.18632","volume":"13","author":[{"given":"El\u017cbieta","family":"Z\u0142owocka-Per\u0142owska","sequence":"first","affiliation":[{"name":"Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland"},{"name":"These authors contributed equally to this work"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"van de Wetering","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Biochemistry, Pomeranian Medical University, Szczecin, Poland"},{"name":"These authors contributed equally to this work"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"To\u0142oczko-Grabarek","sequence":"additional","affiliation":[{"name":"Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland"},{"name":"These authors contributed equally to this work"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J.","family":"Scott","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences and Pharmacy, Centre for Information-Based Medicine, Hunter Medical Research Institute, University of Newcastle, Newcastle, NSW 2305, Australia"},{"name":"Division of Molecular Medicine, Pathology North, NSW Pathology, Newcastle, NSW 2305, Australia"},{"name":"These authors contributed equally to this work"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lubi\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland"},{"name":"These authors contributed equally to this work"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1897-4287-3-2-59","article-title":"The 3020insC Allele of NOD2 Predisposes to Cancers of Multiple Organs","volume":"3","author":"Z\u0142owocka","year":"2005","journal-title":"Hered Cancer Clin Pract"},{"key":"2","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1002\/ijc.21760","article-title":"CDKN2A common variant and multi-organ cancer risk--a population-based study","volume":"11","author":"Z\u0142owocka","year":"2006","journal-title":"Int J Cancer"},{"key":"3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10549-005-9057-z","article-title":"Prevalence of the NOD2 3020insC mutation in aggregations of breast and lung cancer","volume":"9","author":"Serwatowski","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10549-004-1250-y","article-title":"The 3020insC allele of NOD2 predisposes to early-onset breast cancer","volume":"8","author":"Lubi\u0144ski","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/1897-4287-2-3-149","article-title":"The NOD2 3020insC Mutation and The Risk of Familial Pancreatic Cancer?","volume":"2","author":"Lubi\u0144ski","year":"2004","journal-title":"Hered Cancer Clin Pract"},{"key":"6","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1158\/0008-5472.can-03-3791","article-title":"The NOD2 3020insC mutation and the risk of colorectal cancer","volume":"6","author":"Lubi\u0144ski","year":"2004","journal-title":"Cancer Res"},{"key":"7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10549-005-9116-5","article-title":"Association between early-onset breast and laryngeal cancers","volume":"9","author":"Lubi\u0144ski","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10549-006-9382-x","article-title":"CDKN2A-positive breast cancers in young women from Poland","volume":"10","author":"Lubi\u0144ski","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"9","first-page":"835","article-title":"CDKN2A common variants and their association with melanoma risk: a population-based study","volume":"6","author":"Lubinski","year":"2005","journal-title":"Cancer Res"},{"key":"10","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1136\/jmg.2005.031476","article-title":"A common variant of CDKN2A (p16) predisposes to breast cancer","volume":"4","author":"Swiec","year":"2005","journal-title":"J Med Genet"},{"key":"11","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1002\/ijc.22210","article-title":"MC1R common variants, CDKN2A and their association with melanoma and breast cancer risk","volume":"11","author":"Maleszka","year":"2006","journal-title":"Int J Cancer"},{"key":"12","first-page":"S23","article-title":"Breast cancer susceptibility genes","volume":"1","author":"Lener","year":"2007","journal-title":"J BUON"},{"key":"13","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1365-2141.2006.06141.x","article-title":"Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma","volume":"13","author":"Roman","year":"2006","journal-title":"Br J Haematol"},{"key":"14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(05)70434-4","article-title":"Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium","volume":"7","author":"Brooks-Wilson","year":"2006","journal-title":"Lancet Oncol"},{"key":"15","doi-asserted-by":"publisher","first-page":"101489","DOI":"10.18632\/oncotarget.21547","article-title":"NOD2 maybe a biomarker for the survival of kidney cancer patients","volume":"8","author":"Tian","year":"2017","journal-title":"Oncotarget"},{"key":"16","doi-asserted-by":"publisher","first-page":"e89340","DOI":"10.1371\/journal.pone.0089340","article-title":"NOD2 polymorphisms associated with cancer risk: a meta-analysis","volume":"9","author":"Yuan","year":"2014","journal-title":"PLoS One"},{"key":"17","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.humimm.2011.06.003","article-title":"Role of NOD1\/CARD4 and NOD2\/CARD15 gene polymorphisms in cancer etiology","volume":"7","author":"Kutikhin","year":"2011","journal-title":"Hum Immunol"},{"key":"18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1471-2407-8-112","article-title":"Inflammatory response gene polymorphisms and their relationship with colorectal cancer risk","volume":"8","author":"Lubi\u0144ski","year":"2008","journal-title":"BMC Cancer"},{"key":"19","first-page":"CR480","article-title":"NOD2\/CARD15 polymorphism in patients with rectal cancer","volume":"1","author":"Malenczyk","year":"2008","journal-title":"Med Sci Monit"},{"key":"20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/00008469-200504000-00010","article-title":"NOD2 variants and the risk of malignant melanoma","volume":"1","author":"Mierzejewski","year":"2005","journal-title":"Eur J Cancer Prev"},{"key":"21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1897-4287-4-1-15","article-title":"The NOD2 3020insC Mutation in Women with Breast Cancer from the Bydgoszcz Region in Poland. First Results","volume":"4","author":"Laskowski","year":"2006","journal-title":"Hered Cancer Clin Pract"},{"key":"22","first-page":"544","article-title":"The 3020insC NOD2 gene mutation in patients with ovarian cancer","volume":"7","author":"Spaczy\u0144ski","year":"2008","journal-title":"Ginekol Pol"},{"key":"23","first-page":"400","article-title":"Significance of p16 gene and p21 gene expression abnormality in the prognosis of bladder carcinoma: a meta-analysis","volume":"2","author":"Wang","year":"2006","journal-title":"Chinese Journal of Urology"},{"key":"24","doi-asserted-by":"publisher","first-page":"5259602","DOI":"10.1155\/2016\/5259602","article-title":"Prognostic and Clinicopathological Significance of Downregulated p16 Expression in Patients with Bladder Cancer: A Systematic Review and Meta-Analysis","volume":"201","author":"Chen","year":"2016","journal-title":"Dis Markers"},{"key":"25","doi-asserted-by":"publisher","first-page":"153453","DOI":"10.1016\/j.prp.2021.153453","article-title":"Mutant CDKN2A regulates P16\/p14 expression by alternative splicing in renal cell carcinoma metastasis","volume":"22","author":"Lai","year":"2021","journal-title":"Pathol Res Pract"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28226","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T07:11:40Z","timestamp":1657696300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,4,22]]}},"alternative-id":["28226","35478773"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28226","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,22]]}}}